tiprankstipranks
Trending News
More News >
Stoke Therapeutics Inc (STOK)
NASDAQ:STOK

Stoke Therapeutics (STOK) AI Stock Analysis

Compare
389 Followers

Top Page

ST

Stoke Therapeutics

(NASDAQ:STOK)

Rating:78Outperform
Price Target:
$12.50
▲(8.89%Upside)
Stoke Therapeutics earns a strong overall score due to its robust financial performance, highlighted by revenue growth and improved profitability. The technical analysis supports this with positive momentum indicators. Valuation metrics are favorable, underscoring the stock's attractiveness. Corporate events, though not directly weighted, enhance the company's market positioning and growth prospects.
Positive Factors
Clinical Development
The zorevunersen pivotal Phase 3 EMPEROR trial in Dravet Syndrome has recently opened for enrollment, suggesting progress in clinical development.
Product Differentiation
Inclusion of positive behavioral and cognitive benefit data on the label can help differentiate zorevunersen from currently available seizure reduction drugs that do not help with cognition or behavior.
Strategic Collaboration
The collaboration with Biogen on zorenuversen makes significant strategic sense due to Biogen's expertise and global commercial capabilities.
Negative Factors
Market Sentiment
The investment community is less sure of Zorevenersen's place in the treatment landscape despite end-user enthusiasm.
Price Target Adjustment
Lowering P/E multiples and increasing discount rates to better align with current investor sentiment, elevated cost of capital, and reduced appetite for early-stage clinical risk reduces the price target to $35 from $47.

Stoke Therapeutics (STOK) vs. SPDR S&P 500 ETF (SPY)

Stoke Therapeutics Business Overview & Revenue Model

Company DescriptionStoke Therapeutics (STOK) is a biotechnology company focused on pioneering RNA-based medicines to treat severe genetic diseases. Operating within the healthcare and biotechnology sectors, the company specializes in developing treatments for conditions caused by genetic mutations with a focus on precision medicine. Its core product is the proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform, which is designed to selectively increase protein production to achieve therapeutic benefits.
How the Company Makes MoneyStoke Therapeutics makes money primarily through the development and commercialization of its RNA-based therapies, leveraging its TANGO platform. The company generates revenue through research collaborations, licensing agreements, and potential future sales of approved therapies. Collaborations with pharmaceutical partners provide funding and milestone payments, while licensing agreements contribute to upfront payments and royalties based on product sales. These strategic partnerships are significant to Stoke's earnings as they help finance the research and development of its therapeutic candidates.

Stoke Therapeutics Financial Statement Overview

Summary
Stoke Therapeutics shows strong revenue growth and a high gross profit margin, with a transition to profitability and improved cash flow management. The balance sheet is solid with minimal leverage, though increasing liabilities could be a future risk.
Income Statement
75
Positive
Stoke Therapeutics demonstrates strong revenue growth, with a significant increase in total revenue over the TTM period compared to previous years. Gross profit margin is high at 98.25% for TTM, indicating efficient production operations. The net profit margin turned positive at 26.33% TTM, showing improved profitability. However, historical EBIT and EBITDA margins were negative, reflecting past operational challenges.
Balance Sheet
70
Positive
The company maintains a robust balance sheet with a low debt-to-equity ratio of 0.01, indicating minimal leverage and strong financial health. Return on equity is impressive at 14.36% TTM, signaling effective use of equity. The equity ratio of 86.06% suggests high financial stability. However, a historical trend of increasing liabilities could pose future risks.
Cash Flow
80
Positive
The cash flow statement highlights substantial improvements with a positive free cash flow of $69.2M TTM, up from negative values in prior years. Operating cash flow is robust, with a positive ratio to net income of 1.38, indicating efficient cash generation relative to earnings. The free cash flow to net income ratio of 1.38 further confirms strong cash flow management.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue190.91M36.55M8.78M12.40M0.000.00
Gross Profit187.58M32.11M8.78M8.87M-2.23M-1.93M
EBITDA39.79M-99.19M-112.30M-102.81M-83.58M-50.32M
Net Income50.27M-88.98M-104.70M-93.11M-84.71M-50.61M
Balance Sheet
Total Assets406.89M271.56M228.34M256.07M238.87M297.93M
Cash, Cash Equivalents and Short-Term Investments357.32M216.90M201.39M229.59M219.81M287.31M
Total Debt2.35M2.32M2.06M2.36M1.51M80.00K
Total Liabilities56.81M42.53M68.78M71.22M21.09M11.85M
Stockholders Equity350.07M229.02M159.56M184.85M217.78M286.08M
Cash Flow
Free Cash Flow69.20M-87.05M-82.68M-35.83M-68.11M-43.27M
Operating Cash Flow69.54M-86.85M-81.07M-31.87M-66.91M-42.22M
Investing Cash Flow-103.83M-107.47M105.95M-45.88M-76.43M-1.05M
Financing Cash Flow130.75M131.09M53.01M46.41M1.28M108.11M

Stoke Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price11.48
Price Trends
50DMA
10.36
Positive
100DMA
9.20
Positive
200DMA
10.59
Positive
Market Momentum
MACD
0.39
Positive
RSI
58.05
Neutral
STOCH
38.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STOK, the sentiment is Positive. The current price of 11.48 is below the 20-day moving average (MA) of 11.51, above the 50-day MA of 10.36, and above the 200-day MA of 10.59, indicating a neutral trend. The MACD of 0.39 indicates Positive momentum. The RSI at 58.05 is Neutral, neither overbought nor oversold. The STOCH value of 38.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STOK.

Stoke Therapeutics Risk Analysis

Stoke Therapeutics disclosed 67 risk factors in its most recent earnings report. Stoke Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks

Stoke Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
$626.77M14.5920.50%2333.50%
59
Neutral
$519.43M
54
Neutral
$622.35M-45.46%-78.26%15.41%
54
Neutral
$622.74M181.41%3055.71%-18.80%
46
Neutral
C$194.28M-4.22-8.60%2.64%13.54%-1.44%
34
Underperform
$407.93M-45.82%10.38%
33
Underperform
$719.52M-71.44%19.94%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
STOK
Stoke Therapeutics
11.48
-1.46
-11.28%
PHAT
Phathom Pharmaceuticals
8.92
-1.51
-14.48%
RLAY
Relay Therapeutics
3.63
-2.85
-43.98%
SANA
Sana Biotechnology
3.19
-1.89
-37.20%
ERAS
Erasca
1.44
-0.91
-38.72%
MAZE
Maze Therapeutics, Inc.
11.50
-3.50
-23.33%

Stoke Therapeutics Corporate Events

Executive/Board ChangesShareholder Meetings
Stoke Therapeutics Adopts Key Proposals at Annual Meeting
Neutral
Jun 4, 2025

On June 3, 2025, Stoke Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders, where several key proposals were adopted. These included the election of three Class III directors, the ratification of KPMG LLP as the independent registered public accounting firm for 2025, and the approval of executive compensation and its future advisory vote frequency. These decisions are expected to influence the company’s governance and operational strategies moving forward.

The most recent analyst rating on (STOK) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Stoke Therapeutics stock, see the STOK Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
Stoke Therapeutics Launches Phase 3 EMPEROR Study
Positive
Jun 4, 2025

Stoke Therapeutics announced the initiation of their Phase 3 EMPEROR study for zorevunersen, with the first U.S. sites starting in May 2025. This study aims to evaluate the effectiveness of zorevunersen as a potential first-in-class therapy for Dravet syndrome, a severe genetic epilepsy. The announcement marks a significant step in the company’s efforts to address unmet medical needs in this area, potentially impacting their market positioning and offering hope for stakeholders involved in Dravet syndrome treatment.

The most recent analyst rating on (STOK) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Stoke Therapeutics stock, see the STOK Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 05, 2025